Table 3.
The key differences between the current study and other reports.
| Study | Enrolled patients | Treatments | Baseline HBV DNA | Baseline HBsAg | Course | HBsAg loss/seroconversion | Ref. |
|---|---|---|---|---|---|---|---|
| Our study | Decompensated cirrhosis | PEG-IFN-α-2b monotherapy for treatment-naïve and add-on for NAs-experienced | Detectable (> 50 IU/mL) in 53.70% patients | 1,668 IU/mL | 48 weeks | 5.56%/3.70% | |
| OSST | HBeAg-positive CHB patients, ETV experienced | Switch to PEG-IFN-α-2a monotherapy | ≤1,000 copies/ml | 3.3 log10IU/ml | 48 weeks | 8.5%/4.3% | (22) |
| New Switch | HBeAg-negative CHB patients, NAs experienced | Switch to PEG-IFN-α-2a monotherapy | <200 IU/mL | 3.2 log10IU/ml | 48 weeks or 96 weeks | 14.4%/13.1% (48 weeks) 20.7%/16.0% (96 weeks) | (24) |
| Wu et al. | HBeAg-negative CHB patients, NAs experienced | PEG-IFN-α-2a add-on | <100 IU/mL | ≤1,500 IU/mL | 48 weeks | 26.4%/18.7% | (38) |
| Cao et al. | IHC | PEG-IFN-α-2a monotherapy or PEG-IFN-α-2a combined with adefovir | <2,000 IU/mL | <1,000 IU/mL | 48 weeks or 96 weeks | 29.8%/20.2% (48 weeks) 44.7%/38.3% (96 weeks) | (39) |
| Huang et al. | IHC | PEG-IFN-α-2b monotherapy | <2,000 IU/mL | <1,000 IU/mL | 48 weeks | 84.2%/68.4% | (40) |
| Wen et al. | IHC and NAs-experienced | PEG-IFN-α-2b monotherapy for IHC; PEG-IFN-α-2a add-on for NAs-experienced | <2,000 IU/mL | <1,000 IU/mL | 48 weeks | 65.5%/47.3% (IHC) 52.9%/34.3% (NAs-experienced) | (41) |
| Wu et al. | IHC | PEG-IFN-α-2a or PEG-IFN-α-2b monotherapy | <2,000 IU/mL | <1,500 IU/mL | 48 weeks | 47.9%/36.6% | (42) |
| Ning et al. | IHC | PEG-IFN-α-2b monotherapy or with a lead-in period of GM-CSF and vaccine treatment before each cycle | <2,000 IU/mL | <1,500 IU/mL | 68 weeks | 46.67%/40.74% | (43) |
PEG-IFN-α, pegylated interferon-α; NAs, nucleos(t)ide analogs; ETV, entecavir; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; IHC, inactive HBsAg carrier; GM-CSF, granulocyte-macrophage colony stimulating factor.